When the formulation is given as an IV, beta-apoprotein of the blood becomes attached to the surface of the nanoparticles (LDLN) and function as a ligand, thus imparting the affinity to the carrier to be actively taken up by tumor cells which overexpress the LDL receptors during their growth. Here, LDLR is linked to neoplasm.